These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 17401024)

  • 1. Is prophylactic cranial irradiation a possible option for human epidermal growth factor receptor 2-positive breast cancer?
    Buyukhatipoglu H; Sevinc A; Pehlivan Y; Camci C
    J Clin Oncol; 2007 Apr; 25(10):1292; author reply 1293. PubMed ID: 17401024
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors affecting the prognosis of breast cancer patients with brain metastases.
    Saip P; Cicin I; Eralp Y; Kucucuk S; Tuzlali S; Karagol H; Aslay I; Topuz E
    Breast; 2008 Oct; 17(5):451-8. PubMed ID: 18455400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human epidermal growth factor receptor 2 testing in breast cancer.
    Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
    J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
    [No Abstract]   [Full Text] [Related]  

  • 4. In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.
    Neven P; Brouckaert O; Van Belle V; Vanden Bempt I; Hendrickx W; Cho H; Deraedt K; Van Calster B; Van Huffel S; Moerman P; Amant F; Leunen K; Smeets A; Wildiers H; Paridaens R; Vergote I; Christiaens MR
    J Clin Oncol; 2008 Apr; 26(10):1768-9; author reply 1769-71. PubMed ID: 18519273
    [No Abstract]   [Full Text] [Related]  

  • 5. Human epidermal growth factor receptor 2 testing recommendation.
    Raji A
    J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
    [No Abstract]   [Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
    Hameed O; Chhieng D; Adams AL
    J Clin Oncol; 2008 Mar; 26(9):1571. PubMed ID: 18349417
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylactic cranial irradiation in advanced breast cancer: a case for caution.
    Huang F; Alrefae M; Langleben A; Roberge D
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):752-8. PubMed ID: 18954943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancer: clinicopathological characteristics and treatment strategies.
    Akiyama F; Iwase H
    Breast Cancer; 2009; 16(4):252-3. PubMed ID: 19506994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fatal headache from breast cancer].
    Füessl HS
    MMW Fortschr Med; 2005 Dec; 147(51-52):31. PubMed ID: 16402703
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prevention strategies for brain metastases from HER2-positive breast cancer].
    Le Tourneau C
    Bull Cancer; 2011 Apr; 98(4):445-9. PubMed ID: 21540148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications of therapy in cancer patients: Case 3. Toxic epidermal necrolysis induced by oral phenobarbital and whole-brain radiotherapy in a breast cancer patient.
    Vincenzi B; Santini D; Grilli C; La Cesa A; Dianzani C; Tonini G
    J Clin Oncol; 2004 Nov; 22(22):4649-51. PubMed ID: 15542817
    [No Abstract]   [Full Text] [Related]  

  • 13. Images in clinical medicine. Cerebral metastases in breast cancer.
    Rouse H; Dawson SJ
    N Engl J Med; 2005 Oct; 353(16):1724. PubMed ID: 16236743
    [No Abstract]   [Full Text] [Related]  

  • 14. Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy.
    Niwińska A; Tacikowska M; Pieńkowski T
    Acta Oncol; 2007; 46(7):1027-9. PubMed ID: 17851845
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic cranial irradiation in small-cell lung cancer.
    Khandelwal SR; Ghaemmaghami M
    N Engl J Med; 2007 Nov; 357(19):1978; author reply 1978. PubMed ID: 17992730
    [No Abstract]   [Full Text] [Related]  

  • 17. Prophylactic cranial irradiation in small-cell lung cancer.
    Fujiwara Y; Hotta K; Kiura K
    N Engl J Med; 2007 Nov; 357(19):1977-8; author reply 1978. PubMed ID: 17992731
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluorescent in situ hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test?
    Arena V; Pennacchia I; Carbone A; Capelli A
    J Clin Oncol; 2009 Jul; 27(19):e8; author reply e9-10. PubMed ID: 19470909
    [No Abstract]   [Full Text] [Related]  

  • 19. Triple negative, basal cell type and EGFR positive invasive breast carcinoma in Kuwaiti and British patients.
    Ayad E; Francis I; Peston D; Shousha S
    Breast J; 2009; 15(1):109-11. PubMed ID: 19077133
    [No Abstract]   [Full Text] [Related]  

  • 20. Models support prophylactic cranial irradiation.
    Mehta MP
    J Clin Oncol; 2006 Aug; 24(22):3524-6. PubMed ID: 16877718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.